Search

Your search keyword '"Ladon, Dariusz"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Ladon, Dariusz" Remove constraint Author: "Ladon, Dariusz"
24 results on '"Ladon, Dariusz"'

Search Results

1. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

2. Unraveling facets of MECOM-associated syndrome: somatic genetic rescue, clonal hematopoiesis, and phenotype expansion

3. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program

5. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

6. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

7. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

8. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

9. TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL

10. A novel human fetal liver-derived model reveals that MLL-AF4 drives a distinct fetal gene expression program in infant ALL

12. DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study

16. Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects

17. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

18. Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort

19. TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

20. TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

23. Donor lymphocyte infusion followed by interferon-α plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation

24. Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.

Catalog

Books, media, physical & digital resources